PuSH - Publikationsserver des Helmholtz Zentrums München

Wei, X. ; Verma, A.K. ; Jäger, J. ; Porras-Gonzalez, D.L. ; Shen, L. ; Wögrath, M. ; Yildirim, A.Ö. ; Gerckens, M. ; Burgstaller, G.

Phenotypic drug screening for novel antifibrotic therapeutics in lung health.

In: Phenotypic Screening. Berlin [u.a.]: Springer, 2026. 227-240 (Methods Mol. Biol. ; 2989)
DOI PMC
Open Access Green möglich sobald Postprint bei der ZB eingereicht worden ist.
Lung diseases are among the leading causes of death worldwide. Still, noncommunicable pulmonary diseases, such as chronic obstructive pulmonary disease (COPD), and interstitial lung disease (ILD), are lacking curative pharmacotherapies. Either degradation or excessive production of altered pulmonary extracellular matrix (ECM) is a common key feature of those devastating diseases, respectively. Recapitulating those pathological changes in miniaturized cell culture models is key for phenotypic drug discovery approaches targeting the ECM for novel pharmacotherapies in pulmonary disease. We describe here a phenotypic immunofluorescence-based high-content/high-throughput assay in 384-well plate format to measure ECM deposition activity by primary human lung fibroblasts (phLFs) in a pulmonary fibrosis disease context.
Altmetric
Weitere Metriken?
[➜Einloggen]
Zusatzinfos bearbeiten [➜Einloggen]
Publikationstyp Artikel: Sammelbandbeitrag/Buchkapitel
Schlagwörter Ecm Deposition ; Fibroblast ; High-throughput Screening ; Lung Fibrosis ; Phenotypic Drug Screening
ISSN (print) / ISBN 1064-3745
e-ISSN 1940-6029
Bandtitel Phenotypic Screening
Zeitschrift Methods in Molecular Biology
Quellenangaben Band: 2989, Heft: , Seiten: 227-240 Artikelnummer: , Supplement: ,
Verlag Springer
Verlagsort Berlin [u.a.]
Begutachtungsstatus Peer reviewed
Institut(e) Institute of Lung Health and Immunity (LHI)